Physician profile
Mary E Beegle
NPI 1659488419
$2,973.33
in general payments reported to CMS, 2019-2025
20 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $510 · 2021: $949 · 2022: $579 · 2023: $299 · 2024: $179 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $650 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.18 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $641.70 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $443.53 | 2021-2023 | Qelbree |
| Neurocrine Biosciences, INC. | $324.24 | 2019-2025 | Ingrezza |
| Abbvie INC. | $305.28 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $232.81 | 2019-2024 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.60 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $164.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $145.67 | 2020-2022 | |
| Eisai INC. | $142.56 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $121.85 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.03 | 2020-2025 | Trintellix |
| Allergan, INC. | $40.81 | 2019-2020 | |
| Indivior INC. | $40.45 | 2019 | |
| Ironshore Pharmaceuticals INC. | $37.15 | 2019 | |
| Alkermes, INC. | $35.03 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $19.54 | 2025 | Auvelity |
| Adlon Therapeutics L.P. | $15.59 | 2021 | |
| Sun Pharmaceutical Industries INC. | $14.60 | 2021 | |
| Shire North American Group INC | $13.83 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Beegle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.